


4th International Electronic Conference on Medicinal Chemistry

1-30 November 2018 chaired by Dr. Jean Jacques Vanden Eynde



Z-Stereoselective Catalytic Synthesis of Natural Acids, Lembehynes, and Acetogenins - Modern Preparations for Medicine

Vladimir A. D'yakonov ^{1,*}, Lilya U. Dzhemileva ¹, Alexey A. Makarov ¹, Regina A. Tuktarova ¹, Svetlana R. Ishmukhametova ¹, Evgenii N. Andreev ¹, and Usein M. Dzhemilev ¹

¹ Institute of Petrochemistry and Catalysis, Russian Academy of Sciences, 141 Prospekt Oktyabrya, Ufa 450075, Russian Federation

* Corresponding author: DyakonovVA@gmail.com




Z-Stereoselective Catalytic Synthesis of Natural Acids, Lembehynes, and Acetogenins - Modern Preparations for Medicine

Graphical Abstract

$$\bigvee_{m}^{OH} \bigvee_{m}^{R}$$

Lembehynes (antitumor and neritogenic activity)



(a)

Substituted 1Z,5Z-dienes (fragrant substances, pheromones, isoprenoids)

$$HO_2C$$

Di-, tri- and polyenic acids

(antitumor, antiviral and antibacterial activity)

Acetogenins

antibacterial activity)



(a)



Abstract:

The report discusses the latest achievements of the authors in developing original methods for stereoselective synthesis of natural acetogenins, higher bis-methylene-separated di- and trienoic acids, lembehynes that are of exceptional interest as low-toxic target antitumor drugs, as well as compounds with neritogenic activity for treating neurodegenerative diseases.

The synthetic approaches to the above listed natural compounds are based on the use at the key stage of the synthesis, of new organometallic reactions, such as Ti-catalyzed homo- and cross-cyclomagnesiation of 1,2-dienes, involving available Grignard reagents.

The studies of the synthesized compounds for their antitumor and antibacterial activities *in vitro* were performed with the use of unique equipment in "Centre for Molecular Design and Biological Screening of Candidate Substances for the Pharmaceutical Industry" at the Institute of Petrochemistry and Catalysis of RAS using modern methods such as flow cytofluorometry, fluorescence microscopy and Western blotting.

For compounds that showed the greatest activity, in vivo tests were performed for linear mice with grafted malignant Lewis carcinoma.

Key words: Natural acetogenins; Higher bis-methylene-separated(interrupted) di- and trienoic acids; Lembehynes; Antitumor drugs; Neritogenic activity.





1,2-DIENES IN STEREOSELECTIVE SYNTHESIS OF ALKENES

Hydrometalation of 1,2-dienes



S. Nagahara et el. Bull. Chem. Soc. Jpn., 1993, 66, 3783.

Cycloalumination of 1,2-dienes

$$R = \frac{\text{Et}_3 \text{Al}, [Zr]}{\text{CH}_2 \text{Cl}_2, \sim 90\%} \quad R = \frac{\text{H}^+}{\text{Al}} \quad R = \frac{\text{Pr}}{\text{Et}}$$

U.M. Dzhemilev et al. Russ. Chem. Bull. 2002, 51, 2255.

Cyclomagnesiation of 1,2-dienes


$$R = \frac{\text{EtMgHal, [Ti]}}{\text{THF, 85-92\%}} \quad R = \frac{\text{Mg}}{\text{Mg}} \quad R = \frac{\text{H}^{+}}{\text{Rg}} \quad R = \frac{\text{H}^{+}}{\text{Z,Z}} = \sim 98\%$$

U.M. Dzhemilev et al. Tetrahedron., 2004, 60, 1287.






INTERMOLECULAR CYCLOMAGNESIATION OF ALKYL(ARYL) ALLENES AND N,O-CONTAINING 1,2-DIENES



 $[Ti] = Cp_2TiCl_2; R = Et, i-Pr, -(CH_2)_5-, -C_2H_4-O-C_2H_4-.$

N-containing 1,2-diene:cyclo-1,2-diene:EtMgBr:Mg:[Ti] = 10:12:26:20:1; Et₂O, 6 h, r. t.



O-containing 1,2-diene:cyclo-1,2-diene:EtMgBr:Mg:[Ti] = 10:11:24:20:0.5; Et₂O, 6 h, r. t.


V.A. D'yakonov, A.A. Makarov, E.Kh. Makarova, U.M. Dzhemilev, Tetrahedron.— 2013, V. 69, P. 8516-8526








NATURAL SOURCES OF 5Z,9Z-DIENOIC ACIDS




















Efficient inhibitors of topoisomerases I and II; simultaneously exhibit antitumor, antiviral, antiparasitic and antibacterial activities










KNOWN METHODS FOR THE SYNTHESIS OF 5*Z*,9*Z*-DIENOIC ACIDS




N.M. Carballeira, A. Emiliano, A. Guzman. Chem. Phys. Lipids, 100, (1999), 33-40

N.M. Carballeira, J.E. Betancourt, E.A. Orellano, F.A. Gonzalez. J. Nat. Prod, 65, (2002), 1715-1718



Prof. Nestor Carballeira University of Puerto Rico



J. Adrian , C. B. W. Stark, Eur. J. Org. Chem, 27, (2016), 4607-4610



Prof. Christian B. W. Stark Universität Hamburg







EFFICIENT SYNTHESIS OF 5*Z*,9*Z*-DIENOIC ACIDS

Known

Natural 5*Z*,9*Z*-dienoic acids

$$R = -(CH_2)_n CH_3$$

(n = 15-30)

Isolated from the marine sponges (Aplysina fistularis, Axinella verrucosa) and seeds (Pinus tabulaeformis)

Carballeira N.M., et al. J. Nat. Prod., 2002, 64, 1715 The cyclomagnesiation reaction of allenes to give 2,5-dialkylidenemagnesacyclopentanes

$$\stackrel{\textstyle \longleftarrow}{R} := \frac{\text{EtMgHal}}{\text{[Ti]}} R \xrightarrow{\text{Mg}} R \xrightarrow{\text{H}_3\text{O+}} R \xrightarrow{\text{R}}$$

Dzhemilev U.M., et al. Tetrahedron, 2004, 60, 1287 D'yakonov V.A., et al. Tetrahedron, 2008, 64, 10188

NEW METHOD:

Stereoselective synthesis of practically important 5*Z*,9*Z*-dienoic acids is based on the new reaction.

$$R \xrightarrow{+} EtMgHal R \xrightarrow{(CH_2)_4-OR'} \frac{H_3O+}{82-85\%}$$


$$R'O-(CH_2)_4 \xrightarrow{-} (CH_2)_4-OR' \frac{[O]}{71-74\%} R \xrightarrow{(CH_2)_3-COOH}$$

Russ.Chem.Bull., 2012, 61(1),158; Russ.J. Org.Chem., 2012, 48(3), 349; Tetrahedron, 2013, 69, 8516; Chem.Commun., 2013, 49, 8401.






IN VITRO STUDY ON TOPOISOMERASE I INHIBITORY ACTIVITY OF THE SYNTHESIZED 5*Z*,9*Z*-DIENOIC ACIDS



V. A. D'yakonov, A. A. Makarov, L. U. Dzhemileva, E. H. Makarova, U. M. Dzhemilev, *Chem. Commun.*, 2013, 49, 8401



	R	Активность
	C ₈ H ₁₇	>10 μM
	$C_{10}H_{21}$	>0.1 μM
	$C_{11}H_{23}$	>2 μM
	$C_{12}H_{25}$	>1 μM






Fig. Electrophoregram of the products of relaxation of supercoiled plasmid DNA in vitro induced by topoisomerase I (Topogen, USA) in the presence of (5Z,9Z)-5,9-eicosadienoic acid. 1. Supercoiled plasmid DNA (pHOT1). 2. Relaxed DNA form (visualization of the set of topoisomers). 3. Negative control with DMSO (concentration 3%). 4. Relaxation reaction of plasmid DNA in the presence of camptothecin (10 μ M). 5–9. Effect of different concentrations of (5Z,9Z)-5,9-eicosadienoic acid on the relaxation of plasmid DNA (5 – 0.75, 6 – 0.5, 7 – 0.25, 8 – 0.1, 9 – 0.01 μ M).





EICOSA-5*Z*,9*Z*-**DIENOIC ACID**





As a tumor model, malignant Lewis lung carcinoma (LLC) was taken, growing as a solid node, metastasizing hematogenically into the lungs, Which is not subjected to spontaneous regression. In the experiments, 53 female C57Bl / 6j mice with an average body weight of 20 g, were used.


- 1) Analysis of survival rates revealed a significant increase in the lifespan of mice under the influence of agent B-1 at a dose of 30 mg / kg relative to the control group and mice in the administration of paclitaxel.
- 2) With intraperitoneal administration during the period of progressive growth of LLC, the agent B-1 effectively retards the growth of the primary node by inhibiting tumor cell division.


<u>Conclusion</u>: The conducted studies reveal, that agent B-1 possesses antitumor properties. They are manifested, when introduced into mice intraperitoneally during tumor progression. The tolerability of the agent B-1 in animals upon course administration of up to 100 mg / kg is good.






EFFECT OF THE POSITION OF THE 12,52-DIENE GROUP ON THE INHIBITORY ACTIVITY OF hTOPI AND hTOPII







V.A. D'yakonov, et al. Med. Chem. Res., 2016, 25(1), 30-39 V.A. D'yakonov, et al. Bioorg. and Med. Chem. Lett., 2015, 25(11), 2405-2408






SYNTHESIS OF STEROID 5*Z*,9*Z*-DIENOIC ACIDS

$$R_{\text{M}}$$
 CO_2H

V.A. D'yakonov, L.U. Dzhemileva, A.A. Makarov, A.R. Mulyukova, R.A. Tuktarova, I.I. Islamov, U.M. Dzhemilev. Russ. Chem. Bull., 2015, 64(9), 2135-2140.





FIRST SYNTHESIS OF 5Z,9Z,13Z-EICOSATRIENOIC ACID



Haliclona cinerea

V. A. D'yakonov, A. A. Makarov, A. R. Salimova, E. N. Andreev, U. M. Dzhemilev, *Mendeleev Communications*, 2017, *27*, 234-236





SYNTHESIS AND IN VITRO STUDY OF CYTOTOXIC ACTIVITY OF STEROID 5Z,9Z-DIENOIC ACIDS

	IC ₅₀	Top I				
_	(MM)	(uM)	(uM)	(uM)	(uM)	Inhib.
Comp.	HEK	Jurkat	K562	Normal	Fibro-	(µM)
	293			Lvmpho-	blasts	
				cvtes		
1a	0.13	0.10	0.25	0.45	0.67	0.02
	±0.02	±0.01	±0.03	±0.06	±0.04	
1b	1.4	8.0	0.28	0.50	0.54	0.04
	±0.09	±0.008	±0.001	±0.003	±0.01	
1c	0.16	0.40	0.28	0.34	0.55	0.02
10	±0.013	±0.01	±0.016	±0.011	±0.01	
1d	0.19	0.13	0.25	0.28	0.21	0.06
10	±0.016	±0.04	±0.01	±0.06	±0.06	
1.	0.11	0.18	0.19	4.24	8.28	0.02
1e	±0.010	± 0.001	±0.014	±0.013	±0.016	
	2.6	3.5	3.8	6.6	8.0	0.06
1f	±0.09	±0.1	±0.12	±0.10	±0.15	
1-	0.12	0.26	0.71	1.8	2.0	0.02
1g	±0.07	±0.05	±0.09	±0.16	±0.10	
	22.0	21.5	14.4	18.18	62.4	>500
2	±1.3	±1.2	±1.2	±0.8	±1.2	
Choles-	125.17	133.6	145.4	182.9	145.1	>100
tane	±0.9	±2.3	±1.6	±1.3	±1.6	
Pregne-	78.2	59.6	183.9	143.2	130.1	>100
nolone	±0.5	±0.2	±1.1	±1.2	±3.7	
Andro-	88.2	70.6	135.9	128.2	100.3	>100
sterone	±1.7	±2.1	±2.1	±1.2	±1.4	
Campto-	25.17	45.4	33.6	60.9	82.9	0.38
thecin	±0.9	±1.6	±2.3	±1.6	±1.3	
Etopo-	19.45	48.6	34.7	74.5	68.5	>100
side	±0.8	±2.5	±1.5	±1.8	±1.4	


V.A. D'yakonov, L.U. Dzhemileva, R.A. Tuktarova, A.A. Makarov, I.I. Islamov, A.R. Mulyukova, U.M. Dzhemilev. Steroids, 2015, 102, 110-117; V.A. D'yakonov, R. A. Tuktarova, L.U. Dzhemileva, M.M. Yunusbaeva, I.R. Ramazanov, U.M. Dzhemilev. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 1126-1135.







MECHANISM OF TOPOISOMERASE I INHIBITION IN THE PRESENCE OF STEROID 5*Z*,9*Z*-DIENOIC ACIDS



V.A. D'yakonov, R.A. Tuktarova, L.U. Dzhemileva, M.M. Yunusbaeva, I.R. Ramazanov, U.M. Dzhemilev. Novel Hybrid Molecules on the Basis of Steroids and (5Z,9Z)-Tetradeca-5,9-dienoic Acid: Synthesis, Anti-Cancer Studies and Human Topoisomerase I Inhibitory Activity. *Anti-Cancer Agents in Medicinal Chemistry*, 2017, 17, 1126-1135.










Total Synthesis of Muricadienin, the Putative Key Precursor in the Solamin Biosynthesis

Juliane Adrian and Christian B. W. Stark*

Fachbereich Chemie, Institut für Organische Chemie, Universität Hamburg, Martin-Luther-King Platz 6, 20146 Hamburg, Germany

Supporting Information

ABSTRACT: The first total synthesis of muricadienin, the unsaturated putative precursor in the biosynthesis of *trans*- and *cis*-solamin is described. Key steps in the synthesis are a chemoselective hydroboration, a Z-selective Wittig reaction, and a Fries rearrangement for introducing the terminal α -substituted butenolide. Thus, muricadienin can be synthesized in 11 steps from commercially available starting materials in 42% overall yield.




Org. Lett., 2014, 16 (22), pp 5886–5889







ORIGINAL METHOD FOR THE SYNTHSIS OF MURICADIENIN AND ITS ANALOGS — THE FOUNDATION FOR THE DEVELOPMENT MODERN ANTIBACTERIAL, ANTIVIRAL AND ANTITUMOR DRUGS




Isolated from the roots

of the plant *Annona* muricata

Can be synthesized in 11 stages in 42% yield

Org. Lett., 2014, 16 (22), pp 5886–5889



Usein M. Dzhemilev; Vladimir A. D'yakonov; Regina A. Tuktarova; Lilya U. Dzhemileva; Svetlana R. Ishmukhametova; Milyausha M. Yunusbaeva; Armin de Meijere; *J. Nat. Prod.* August 17, 2016 (Article) pp 2039–2044







BRAIN DISEASES - THE EPIDEMIC OF THE XXI CENTURY

Prevalence of socially significant diseases:

- Neurological / Mental
- Cardiovascular
- Oncological

PROGNOSES


Disease 2009 2040

million people

Parkinson's Disease 16 32

Alzheimer's Disease 25 75

In the world: 2013 - 44.5 million, 2030 - 75.5 million; 2050 - 135.5 million people



Russia: 1.4 - 1.8 million people


Extract from G8 Science Ministers and Presidents of Science Academies protocol (London UK, 12 June 2013)

«...Cooperation in the field of <u>neurodegenerative diseases</u> is considered as <u>an example of global challenges</u> involving the creation of a global research infrastructure, which is confirmed by <u>increased funding</u> for this in the US and Canada, as well as by organizing relevant research centers in Paris and Bonn.»






CURRENT CONCEPTS OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT OF NEURODEGENERATIVE DISEASES



Nonspecific neuronal cell death mechanisms

- ✓ Increased secretion of growth factors
- ✓ Activation of antioxidant systems








BASIC CONCEPT IN THE TREATMENT OF NEURODEGENERATIVE DISEASES (NDD)

Most NDD causes changes in the chemical communication system in the neural tissue

Oxidative stress because of the mitochondria destruction

Apoptosis of neurons and microglia



Neurotrophic factors as neuroprotectors upon neurodegenerative diseases

Neurotrophic (growth) factors (BDNF, GDNF, NGF, FGF, etc.)

Problem with addressable delivery!



Drugs

SEMAX (Met-Glu-His-Phe-Pro-Gly_Pro) **SELANK** (Thr-Lys-Pro-Arg-Pro-Gly-Pro)

EXPENSIVE! And not always effective! Quickly destroyed!









LEMBEHYNES - EFFICIENT NEURITOGENIC COMPOUNDS

Prof. Motomasa Kobayashi Osaka University

$$C_{16}H_{33}$$
Lembehyne A
$$C_{16}H_{33}$$

$$C_{16}H_{33}$$

$$C_{15}H_{31}$$

$$C_{15}H_{31}$$

$$C_{15}H_{31}$$

$$C_{15}H_{31}$$

$$C_{15}H_{31}$$







TOTAL SYNTHESIS OF LEMBEHYNE A

$$(CH_2)_{14}CH_3 \xrightarrow{a, b, c} H$$

$$(CH_2)_{14}CH_3 \xrightarrow{d, e, f} (CH_2)_{14}CH_3$$

lembehyne A

Scheme: Reagents and conditions: (a) HC=CCH₂CH₂CH₂CH₂OH, "BuLi, THF, HMPA, -78 to 10°C, 80%; (b) Dess-Martin periodinane, CH₂Cl₂, rt, 85%; (c) CH₃COCN₂PO(OMe)₂, K₂CO₃, MeOH, rt, 84%; (d) ICH₂CH₂CH₂CH₂OTBS, "BuLi, THF, HMPA, -40°C to rt, 75%; (e) H₂, Pd/BaSO₄, quinoline, EtOH, rt; (f) TBAF, THF, rt, 89% two steps; (g) Dess-Martin periodinane, CH₂Cl₂, rt, 84%; (h) CH₃COCN₂PO(OMe)₂, K₂CO₃, MeOH, rt, 72%; (i) 6, "BuLi, THF, HMPA, -40 to 0°C, 68%; (j) TBAF, THF, rt, 75%.





sponsors:



PREPARATION OF THE KEY MONOMER IN THE SYNTHESIS OF LEMBEHYNE A

Cp₂TiCl₂ (10 mol%)
EtMgBr (4 eq.)
Mg (3 eq.)
$$Et_2O, rt, 6 h$$

$$OTHP$$


V.A. D'yakonov, L.U. Dzhemileva, A.A. Makarov, E.N. Andreev, U.M. Dzhemilev, Russ. J. Org. Chem., 2016, V. 52(12), 1844–1846;

V.A. D'yakonov, A.A. Makarov, L.U. Dzhemileva, E.N. Andreev, U.M. Dzhemilev. Total Synthesis of Neuritogenic Alkynes: Lembehyne B and Key Intermediate of Lembehyne A. *ChemistrySelect*, 2017, *2*, 1211.





CROSS-CYCLOMAGNESIATION FOR THE SYNTHESIS OF NEIRITOGENIC ALKYNE — LEMBEHYNE B



V. A. D'yakonov, A. A. Makarov, L. U. Dzhemileva, E. N. Andreev, U. M. Dzhemilev, Mendeleev Communications, 2017, 27, 122-124; L.U. Dzhemileva, V.A. D'yakonov, A.A. Makarov, E.N. Andreev, M.M. Yunusbaeva, U.M. Dzhemilev, *Org. Biomol. Chem.* 2017, *15*, 470.





PREPARATION OF NATURAL LEMBEHYNE B AND ITS SYNTHETIC ANALOGS INVOLVING THE WEINREB AMID


$$R \longrightarrow \frac{1}{+} \longrightarrow$$









IN VITRO ANALYSIS OF CELL CYCLE OF LEMBEHYNE B ON THE LEUKEMIA CELL LINES AND NEUROBLASTOMA CELLS







Cell cycle progression in Jurkat cells



The cell cycle in Jurkat cells without treatment with Lembehyne B



Cell cycle progression in Neuro2A cells











STUDY OF NEURITOGENIC ACTIVITY OF LEMBEHYNE ON NEURO2A CELLS


Control – after incubation for 72 h




For 48 h



Incubation for 24 h



For 72 h








STUDY OF NEURITOGENIC ACTIVITY OF LEMBEHYNE B ON NEURO2A CELLS IN COMPARISON WITH NERVE GROWTH FACTOR

Lembehynes

NGF



Differentiation of Neuro2A cells during incubation for 48-72 hours with the addition to the cultivation medium only of lembehyne B (left) and only of NGF (nerve growth factor) (right). Staining with DAPI and ActinRedTM 555 ReadyProbesTM Reagent (InvitrogenTM).





Conclusions

Reactions of catalytic homo- and cross-cyclomagnesiation of aliphatic and functionally substituted allenes using available Grignard reagents are efficient tools for the design and stereoselective synthesis of natural functionally substituted bis-methylene-separated Z-dienes, fatty acids, acetogenins and lembehynes, exhibiting a broad spectrum of biological activities.





Acknowledgments

This work was financially supported by the Russian Science Fundation(Grants 14-13-00263, 16-13-10172, 18-73-10030), Russian Foundation for Basic Research (Grants16-03-00543, 17-43-020502, 18-29-09068) and Grant of the RF President for the support of leading scientific schools(NS-5240.2018.3).



RUSSIAN FOUNDATION FOR BASIC RESEARCH





sponsors:

